New Zealand vs Togo: Pneumococcal conjugate second or third-dose vaccines (PCVc)
New Zealand
89.0%
in 2025
Togo
89.0%
in 2025
New Zealand rank
72nd
Togo rank
72nd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- New Zealand
- Togo
How they compare
New Zealand currently reports 89.0% against 89.0% in Togo, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Togo ahead.
New Zealand ranks 72nd and Togo ranks 72nd of 194 countries.
Across the 3 decades both report, New Zealand averaged higher in 2 and Togo in 1.
Head to head by decade
| Decade | New Zealand | Togo | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 43.5% | 0.0% | 43.5% | New Zealand |
| 2010s | 92.6% | 43.9% | 48.7% | New Zealand |
| 2020s | 82.5% | 89.0% | 6.5% | Togo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), New Zealand or Togo?
- New Zealand, at 89.0% against 89.0% in Togo as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between New Zealand and Togo?
- 0.0%, with New Zealand ahead.
- How many years of comparable data are there for New Zealand and Togo?
- 18 years are reported by both, from 2008 to 2025.
- How do New Zealand and Togo rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- New Zealand ranks 72nd and Togo ranks 72nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.